Effect of 26 Weeks of Liraglutide Treatment on Coronary Artery Inflammation in Type 2 Diabetes Quantified by [<sup>64</sup>Cu]Cu-DOTATATE PET/CT: Results from the LIRAFLAME Trial.

Front Endocrinol (Lausanne) · 2021 · PMC8669791 · PMID 34917038

Europe PMC DOI

hedged sentences

0.0760

closest p · 1.5× alpha

0.0760

boldest claim

The sentences

a borderline significant trendp=0.076so close (0.05 < p ≤ 0.1)

A borderline significant trend was observed when comparing the mean change in SUV max and mSUV max between the 2 groups (SUV max : -0.23 [-0.49 to 0.03] g/ml, p=0.076; mSUV max : -0.21 [-0.46 to 0.03] g/ml, p=0.077) ( Figures 2A, B ).

also in 231 other papers

borderline significantno p-value reported

When comparing the mean change in uptake values between the two groups at both the participant level (SUV max : p=0.076; mSUV max : p=0.077) and the coronary segment level (SUV max : p=0.13; mSUV max : p=0.11) a borderline significant difference was observed.

also in 11,409 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.